Global pharma major Lupin Limited recently announced the re-launch of Humrahi at the Research Society for the Study of Diabetes in India (RSSDI) conference in New Delhi.
“Humrahi is now enhanced with comprehensive support for both diabetes and heart health. With diabetes and cardiovascular diseases ranking among the top health challenges globally, Humrahi represents a critical innovation that combines extensive support for diabetes management along with robust care strategies for heart health. This dual focus aims to offer patients a holistic approach to health management,” the company said in a statement.
This launch builds on the proven success of Humrahi, which has been instrumental in guiding patients toward better diabetes management. The enhanced version now includes cardiovascular care, providing patients with insights into heart-healthy practices, regular monitoring, and expert guidance on managing cardiovascular risks associated with diabetes.
“Humrahi is a unique initiative designed to improve patient outcomes by addressing one of healthcare’s biggest challenges – non-adherence to therapy. It actively supports patients in managing their conditions through value-based support and care, raises awareness, bridging gaps that often prevent adherence and, ultimately, improves health outcomes,” said Rajeev Sibal, President India Region Formulations, Lupin.
Dr. B M Makkar, Organizing Chairman, RSSDI said that Humrahi stands out as it empowers patients to take charge of their own health journey with ease.” Patients can access Humrahi through the Play Store, App Store or it website.
